Brokerages Anticipate Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) to Post -$3.76 Earnings Per Share

Wall Street brokerages expect Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGLGet Rating) to report ($3.76) earnings per share (EPS) for the current quarter, Zacks reports. Zero analysts have made estimates for Madrigal Pharmaceuticals’ earnings. The lowest EPS estimate is ($3.95) and the highest is ($3.35). Madrigal Pharmaceuticals reported earnings of ($3.72) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 1.1%. The firm is scheduled to announce its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that Madrigal Pharmaceuticals will report full year earnings of ($14.55) per share for the current year, with EPS estimates ranging from ($15.98) to ($12.48). For the next year, analysts anticipate that the firm will report earnings of ($11.17) per share, with EPS estimates ranging from ($16.72) to ($7.98). Zacks Investment Research’s EPS averages are an average based on a survey of analysts that cover Madrigal Pharmaceuticals.

Madrigal Pharmaceuticals (NASDAQ:MDGLGet Rating) last released its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($3.36) EPS for the quarter, topping analysts’ consensus estimates of ($3.75) by $0.39. During the same period in the previous year, the company earned ($3.32) earnings per share.

A number of equities research analysts recently weighed in on the stock. Canaccord Genuity Group raised their price target on shares of Madrigal Pharmaceuticals from $133.00 to $151.00 and gave the company a “buy” rating in a report on Thursday, May 12th. StockNews.com initiated coverage on Madrigal Pharmaceuticals in a research note on Thursday, March 31st. They set a “sell” rating for the company. Zacks Investment Research cut Madrigal Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, April 28th. Finally, Oppenheimer lowered their price objective on Madrigal Pharmaceuticals from $180.00 to $170.00 in a research note on Tuesday, May 10th. Two equities research analysts have rated the stock with a sell rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, Madrigal Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $159.00.

Shares of Madrigal Pharmaceuticals stock opened at $74.30 on Thursday. Madrigal Pharmaceuticals has a twelve month low of $52.33 and a twelve month high of $110.29. The stock has a market cap of $1.27 billion, a price-to-earnings ratio of -5.07 and a beta of 1.29. The company has a fifty day moving average price of $74.08 and a 200 day moving average price of $79.95.

Several hedge funds and other institutional investors have recently bought and sold shares of MDGL. Marshall Wace LLP acquired a new stake in Madrigal Pharmaceuticals in the 4th quarter valued at about $52,000. Advisor Group Holdings Inc. grew its position in Madrigal Pharmaceuticals by 183.0% in the third quarter. Advisor Group Holdings Inc. now owns 866 shares of the biopharmaceutical company’s stock worth $70,000 after buying an additional 560 shares during the last quarter. Aaron Wealth Advisors LLC acquired a new position in Madrigal Pharmaceuticals in the first quarter worth approximately $123,000. Ensign Peak Advisors Inc bought a new position in shares of Madrigal Pharmaceuticals in the fourth quarter valued at $132,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Madrigal Pharmaceuticals by 29.2% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,626 shares of the biopharmaceutical company’s stock valued at $160,000 after acquiring an additional 367 shares during the last quarter. Institutional investors and hedge funds own 81.83% of the company’s stock.

About Madrigal Pharmaceuticals (Get Rating)

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis.

See Also

Get a free copy of the Zacks research report on Madrigal Pharmaceuticals (MDGL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Madrigal Pharmaceuticals (NASDAQ:MDGL)

Want More Great Investing Ideas?

Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.